# ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

> **NCT04051502** · EARLY_PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Ovarian Cancer
- Adnexal Mass

## Interventions

- **DRUG:** Method 1: Indocyanine green dye
- **DRUG:** Method 2: Indocyanine green dye
- **DRUG:** Method 3: Indocyanine green dye
- **DRUG:** Method 3: Indocyanine green dye

## Key facts

- **NCT ID:** NCT04051502
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-05
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051502, "ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04051502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*